A5045186633- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Synthesis and Biological Evaluation
- Immune Cell Function and Interaction
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- T-cell and B-cell Immunology
- Cannabis and Cannabinoid Research
- Receptor Mechanisms and Signaling
- Radiopharmaceutical Chemistry and Applications
- Psychedelics and Drug Studies
- Dermatology and Skin Diseases
- Quinazolinone synthesis and applications
- Brain Metastases and Treatment
- Pharmacological Receptor Mechanisms and Effects
- Cancer Treatment and Pharmacology
- Neuroscience and Neuropharmacology Research
- Asthma and respiratory diseases
- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Shionogi (Japan)
2007-2024
Futaba (Japan)
2013-2024
Foxp3-expressing CD25+CD4+ regulatory T cells (Tregs) are abundant in tumor tissues. Here, hypothesizing that Tregs would clonally expand after they activated by tumor-associated antigens to suppress antitumor immune responses, we performed single-cell analysis on characterize them cell receptor clonotype and gene-expression profiles. We found multiclonal present tissues predominantly expressed the chemokine CCR8. In mice humans, CCR8+ constituted 30 80% of various cancers less than 10%...
Although regulatory T cells (Treg) are inhibitory immune that essential for maintaining homeostasis, Tregs infiltrate tumor tissue promote growth by suppressing antitumor immunity. Selective reduction of tumor-infiltrating is, therefore, expected to activate immunity without affecting homeostasis. We previously reported selective Treg depletion targeted a C-C motif chemokine receptor 8 (CCR8) resulted in induction strong any obvious autoimmunity mouse models. Thus, herein, we developed novel...
Epertinib (S-222611) is a potent, reversible, and selective tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), human EGFR2 (HER2), EGFR4. We developed experimental brain metastasis models by intraventricular injection (intraventricular mouse model; IVM) HER2-positive breast cancer (MDA-MB-361-luc-BR2/BR3) or T790M-EGFR-positive lung (NCI-H1975-luc) cells. After single oral administration, epertinib lapatinib concentrations in metastatic regions were analyzed quantitative...
Epidermal growth factor receptor (EGFR) and human epidermal 2 (HER2) are validated molecular targets in cancer therapy. Dual blockade has been explored one such agent, lapatinib, is clinical practice but with modest activity. Through chemical screening, we discovered a novel EGFR HER2 inhibitor, S-222611, that selectively inhibited both kinases IC50 s below 10 nmol/L. S-222611 also intracellular kinase activity the of EGFR-expressing HER2-expressing cells. In addition, showed potent...
Inhibiting the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)-mediated immune checkpoint system using an anti-CTLA-4 antibody (Ab) can suppress growth of various cancers, but detailed mechanisms are unclear. In this study, we established a monoclonal hepatocellular carcinoma cell line (Hepa1-6 #12) and analyzed associated with Ab treatment. Depletion CD4 + T cells, not CD8 prevented Ab-mediated anti-tumor effects, suggesting dependence on cells. Anti-CTLA-4 treatment resulted in...
<p>In vivo anti-tumor activity of S-531011 in CT26.WT or EMT6 tumor-bearing mice model.</p>
<p>The binding activity of S-531011 against various chemokine receptors, PD-1, PD-L1, CTLA4, or mouse CCR8</p>
<p>Concentration of S-531011 in serum and tumor after a single intravenous administration CT26.WT tumor-bearing hCCR8 KI mice.</p>
<div>Abstract<p>While regulatory T cells (Tregs) are inhibitory immune that essential for maintaining homeostasis, Tregs infiltrate tumor tissue promote growth by suppressing anti-tumor immunity. Selective reduction of tumor-infiltrating is therefore expected to activate immunity without affecting homeostasis. We previously reported selective Treg depletion targeted a C-C motif chemokine receptor 8 (CCR8) resulted in induction strong any obvious autoimmunity mouse models. Thus,...
<p>Supplementary Information</p>
<p>Concentration of S-531011 in serum and tumor after a single intravenous administration CT26.WT tumor-bearing hCCR8 KI mice.</p>
<p>Binding profile of the newly created CCR8 antibody</p>
<p>In vivo anti-tumor activity of S-531011 in CT26.WT or EMT6 tumor-bearing mice model.</p>
<p>Supplementary Information</p>
<p>Binding profile of the newly created CCR8 antibody</p>
<p>Generation of humanized CCR8 KI mice</p>
<p>The binding activity of S-531011 against various chemokine receptors, PD-1, PD-L1, CTLA4, or mouse CCR8</p>
<p>Generation of humanized CCR8 KI mice</p>
<p>The binding activity of S-531011 against various chemokine receptors, PD-1, PD-L1, CTLA4, or mouse CCR8</p>
<p>The binding activity of S-531011 against various chemokine receptors, PD-1, PD-L1, CTLA4, or mouse CCR8</p>
<p>Generation of humanized CCR8 KI mice</p>